RxDoctor Payments Data

Matthew Rauen, MD

Ophthalmology · West Des Moines, IANPI 1922216621

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Alcon accounts for 74.8% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $42,665, more than ten times the $1,145 reported in 2019. Among ophthalmology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$108,350in general payments, 2019–2025

Across 240 payments — averaging $451.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$81K
  • Alcon Research LLC$24K
  • US Retina LLC$2K
  • Glaukos Corporation$179
  • Carl Zeiss Meditec, Inc.$165
  • Tarsus Pharmaceuticals, Inc.$50
  • plus $90 from 5 others
$647,423in research payments, 2019–2025

Across 107 payments — averaging $6050.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$647K

What the payments were for

  • Consulting fees$59,06255%
  • Speaking & faculty fees$26,00024%
  • Travel & lodging$12,11511%
  • Food & beverage$8,7698%
  • Ownership interest$2,4032%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,350 in reported general payments places this provider in the 95th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$755,289
Medicare patients
1,148
Services billed
5,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate1,392$65,204
MoxifloxacinMoxifloxacin Hcl1,268$27,794
Fluorometholone68$5,209
ValacyclovirValacyclovir Hcl44$1,909
Ketorolac Tromethamine127$1,790
ErythromycinErythromycin Base36$398
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$278
Tobramycin35$206

Paid to pharmacies, not to this prescriber.

Other ophthalmology in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →